PTC Therapeutics | PTCT - Operating Profit


PTC Therapeutics reported $148.98M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD 37.84M 42.45M Jun/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Amgen USD 4.61B 777M Jun/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
Biogen USD 419.5M 663.3M Sep/2026
BioMarin Pharmaceutical USD 105.6M 24.04M Jun/2026
Cytokinetics USD -179.17M 2.05M Jun/2026
Daiichi Sankyo JPY 108.7B 23.6B Sep/2026
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Gilead Sciences USD 3.85B 1.17B Jun/2026
Incyte USD -707.47M 1.41B Sep/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
Novartis USD 4.75B 515M Jun/2026
Pfizer USD 667M 4.32B Jun/2026
PTC Therapeutics USD 148.98M 103.09M Jun/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Roche Holding CHF 11.46B 1.91B Jun/2026
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sarepta Therapeutics USD 13.29M 345.14M Jun/2026
TG Therapeutics USD 21.67M 13.12M Jun/2026
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026
Xencor USD -36.6M 41.26M Jun/2026